{
    "nctId": "NCT00055991",
    "briefTitle": "Bexarotene in Preventing Breast Cancer in Women at Genetic Risk",
    "officialTitle": "A Multicenter Randomized Double-Blind Trial Of Targretin Capsules Modifying Immunophenotypic Markers Related To Breast Cancer Progression In Breast Tissue From Genetically Identified High Risk Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 87,
    "primaryOutcomeMeasure": "Chemopreventive effect as determine by a modification of the immunophenotypic characteristics of normal breast tissue at day 29 during study treatment and day 30 after study completion",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Known carrier of a BRCA-1 or BRCA-2 mutation\n\n  * Copy of laboratory report stating results must be available for review OR\n* At risk for carrying a BRCA-1 or BRCA-2 mutation\n\n  * At least 10% risk by Parmigiana probability model\n* Must have at least 1 breast that has never been involved with cancer and has not been irradiated\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* WBC greater than 4,000/mm\\^3\n* Platelet count greater than 100,000/mm\\^3\n* Hematocrit greater than 30%\n\nHepatic\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* ALT no greater than 1.5 times ULN\n* Alkaline phosphatase no greater than 1.5 times ULN\n* Albumin no greater than 1.5 times ULN\n* No biliary tract disease\n\nRenal\n\n* Creatinine no greater than 1.5 times ULN\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception for 1 month before, during, and for 1 month after study therapy\n* Triglycerides normal\n* Thyroid-stimulating hormone and thyroxine normal\n* Willing to undergo 2 duplicate needle biopsies of the breast\n* Willing to undergo genetic testing for BRCA-1 and BRCA-2\n* No uncontrolled hyperlipidemia\n* No nontoxic goiter or thyroid enlargement\n* No severe underlying chronic illness or disease\n* No uncontrolled diabetes\n* No history of pancreatitis\n* No cancer within the past year except skin cancer or carcinoma in situ of the cervix (defined from the date of first diagnosis)\n* No concurrent alcohol use (greater than 3 drinks or its equivalent per day)\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* More than 1 year since prior chemotherapy for a neoplasm\n\nEndocrine therapy\n\n* More than 3 months since prior postmenopausal hormonal therapy (including estrogens or progestins)\n* More than 3 months since prior tamoxifen or other selective estrogen-receptor modulators\n* No concurrent hormone replacement therapy\n* Concurrent thyroid hormone supplementation allowed\n\nRadiotherapy\n\n* See Disease Characteristics\n\nSurgery\n\n* Not specified\n\nOther\n\n* More than 30 days since prior investigational medications\n* More than 3 months since prior oral vitamin A supplements greater than the recommended daily requirement (5,000 IU) or therapeutic oral or topical vitamin A derivatives (e.g., isotretinoin)\n* No concurrent participation in a study of an investigational agent\n* No concurrent medications known to be associated with pancreatic toxicity or to increase triglyceride levels",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}